Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
April 14, 2024 Markets Rattle: Iran-Israel Conflict and Economic Data Ahead
Apple’s Technical Climb To $240 By Year-End
April 15, 2024
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading
Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
CAH Stock News and Mentions of Cardinal Health, Inc. Stocktwits
Updated: April 20, 2024 (09:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Cardinal Health Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Cardinal Health, Inc. (CAH).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Cardinal Health stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Cardinal Health, Inc. (CAH)
April 19, 2024 (14:37) / "Zacks Commentary" (by Zacks Equity Research)
Lam Research ( LRCX ) to Post Q3 Earnings: What's in the Cards?
Lam Research's (LRCX) third-quarter fiscal 2024 results are expected to reflect strength in 3D DRAM and advanced packaging amid a slowdown in memory spending.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) Voluson to Aid Women's Health Imaging
GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
AtriCure's ( ATRC ) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
In Article Trend: Somewhat-Bullish
April 19, 2024 (11:59) / "Zacks Commentary" (by Zacks Equity Research)
Intuitive Surgical ( ISRG ) Q1 Earnings Beat, Procedures Robust
Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
In Article Trend: Somewhat-Bullish
April 18, 2024 (16:12) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Texas Instruments ( TXN ) in Q1 Earnings?
Texas Instruments' (TXN) first-quarter 2024 results are likely to reflect the adverse impacts of inventory reduction and macro headwinds.
In Article Trend: Neutral
April 18, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
In Article Trend: Somewhat-Bullish
April 18, 2024 (15:07) / "Zacks Commentary" (by Zacks Equity Research)
IceCure Medical ( ICCM ) Submits Final Cryoablation Data to FDA
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.
In Article Trend: Neutral
April 18, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
At Cencora, Steven H Collis Chooses To Exercise Options, Resulting In $1.60M - Cencora ( NYSE:COR )
Disclosed in a recent SEC filing on April 17, Collis, Chairman at Cencora COR, made a noteworthy transaction involving the exercise of company stock options. What Happened: A Form 4 filing with the U.S.
In Article Trend: Somewhat-Bullish
April 17, 2024 (15:07) / "Zacks Commentary" (by Zacks Equity Research)
Henry Schein ( HSIC ) Global Presence Aids, Macroeconomic Woes Stay
Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:48) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) , RSNA Unite to Aid Breast Cancer Imaging
GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.
In Article Trend: Somewhat-Bullish
April 16, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Revvity's ( RVTY ) Launch to Boost Pharma-Contract Partner Tie-Up
Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:58) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Taiwan Semiconductors' ( TSM ) Q1 Earnings?
Taiwan Semiconductor's (TSM) first-quarter 2024 results are expected to reflect gains from its robust technology portfolio amid headwinds.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
What's in the Offing for ASML Holding's ( ASML ) Q1 Earnings?
ASML Holding's (ASML) first-quarter results are expected to reflect the benefits of strong momentum across the EUV and DUV systems amid macroeconomic headwinds.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Charles River ( CRL ) Stock Now
Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
In Article Trend: Somewhat-Bullish
April 16, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Hurt by Softness in BioPharma and Competition
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
April 16, 2024 (13:38) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Agrees to a Consent Decree With DOJ and FDA
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
In Article Trend: Somewhat-Bullish
April 15, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Cardinal Health ( CAH ) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Cardinal Health (CAH) closed at $107.03, marking a +1.84% move from the previous day.
In Article Trend: Somewhat-Bullish
April 15, 2024 (17:18) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) to Showcase Enhanced Breast Cancer Imaging
GE HealthCare's (GEHC) latest breast cancer detection technology is likely to enhance the detection and diagnosis of breast cancer and improve patient outcomes.
In Article Trend: Somewhat-Bullish
April 15, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) , MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
In Article Trend: Bullish
April 15, 2024 (12:19) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Glaukos ( GKOS ) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:47) / "Zacks Commentary" (by Zacks Equity Research)
QuidelOrtho's ( QDEL ) New Test to Offer Enhanced Opioid Testing
QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.
In Article Trend: Neutral
April 12, 2024 (15:04) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold BD ( BDX ) Stock in Your Portfolio
BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)
Baxter's ( BAX ) New Injectables Aid Its Pharmaceutical Portfolio
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
In Article Trend: Somewhat-Bullish
April 12, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Hologic's ( HOLX ) New Launches Aid, Macroeconomic Issues Ail
Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
In Article Trend: Neutral
April 12, 2024 (13:22) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold The Cooper Companies ( COO ) in Your Portfolio Now
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:22) / "Zacks Commentary" (by Zacks Equity Research)
Glaukos ( GKOS ) Gains Nearly 25% YTD: What's Driving the Rally?
Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp's ( LH ) At-Home Mpox Testing Kit Gets the FDA's EUA Nod
Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.
In Article Trend: Neutral
April 12, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Add Haemonetics ( HAE ) to Your Portfolio Now
Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Cardinal Health, Inc. ( CAH ) is Attracting Investor Attention: Here is What You Should Know
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
April 12, 2024 (12:29) / "Zacks Commentary" (by Zacks Equity Research)
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:35) / "Zacks Commentary" (by Indrajit Bandyopadhyay)
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
In Article Trend: Somewhat-Bullish
April 11, 2024 (10:45) / "Benzinga" (by Zacks)
Boston Scientific ( BSX ) Faces Rising Costs, Competition - Boston Scientific ( NYSE:BSX ) , Cardinal Health ( NYSE:CAH )
Boston Scientific Corporation BSX has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 ( Sell ) currently.
In Article Trend: Neutral
April 10, 2024 (17:35) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add DaVita ( DVA ) to Your Portfolio
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 10, 2024 (17:31) / "Zacks Commentary" (by Zacks Equity Research)
Integer Holdings ( ITGR ) Hits 52-Week High: What's Driving It?
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
In Article Trend: Somewhat-Bullish
April 10, 2024 (15:58) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold Baxter International ( BAX ) in Your Portfolio
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
In Article Trend: Somewhat-Bullish
April 10, 2024 (15:10) / "Zacks Commentary" (by Zacks Equity Research)
Align Technology ( ALGN ) Up 20.5% YTD: Will the Rally Continue?
Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
April 10, 2024 (13:36) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Fresenius Medical ( FMS ) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:33) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Merit Medical ( MMSI ) Stock for Now
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
In Article Trend: Bullish
April 10, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Faces Rising Costs, Competition
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
In Article Trend: Neutral
April 10, 2024 (12:06) / "Zacks Commentary" (by Zacks Equity Research)
Neogen ( NEOG ) Q3 Earnings Miss Estimates, Gross Margin Expands
Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.
In Article Trend: Neutral
April 9, 2024 (15:47) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Retain Integer Holdings ( ITGR ) Stock for Now
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
In Article Trend: Somewhat-Bullish
April 9, 2024 (15:04) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Retain Inari Medical ( NARI ) Stock for Now
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
In Article Trend: Somewhat-Bullish
April 9, 2024 (14:59) / "Zacks Commentary" (by Zacks Equity Research)
Shockwave Medical's ( SWAV ) Reducer Receives Positive Results
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
In Article Trend: Somewhat-Bullish
April 9, 2024 (14:08) / "Benzinga" (by Zacks)
Philips ( PHG ) Boosts Patient Monitoring With SmartQare Deal - AdaptHealth ( NASDAQ:AHCO ) , Cardinal Health ( NYSE:CAH )
Philips PHG is leaving no stone unturned to bolster its patient monitoring solutions portfolio on the back of recent collaborations. In this regard, the company partnered with smartQare to integrate the latter's viQtor solution into its clinical patient monitoring platforms.
In Article Trend: Bullish
April 9, 2024 (13:23) / "Zacks Commentary" (by Zacks Equity Research)
Do Options Traders Know Something About Cardinal Health ( CAH ) Stock We Don't?
Investors need to pay close attention to Cardinal Health (CAH) stock based on the movements in the options market lately.
In Article Trend: Neutral
April 9, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Myriad Genetics ( MYGN ) Stock Now
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp's ( LH ) Strategic Alliances Aid Amid Macroeconomic Woes
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:02) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Introduces Magnet Technology for NMR Adoption
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:41) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Integra ( IART ) Stock Now
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:34) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Launches TSX Universal Series ULT Freezers
Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.
In Article Trend: Somewhat-Bullish
April 9, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF ( JPME ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Cardinal Health ( CAH ) Fell More Than Broader Market
Cardinal Health (CAH) concluded the recent trading session at $109.47, signifying a -0.41% move from its prior day's close.
In Article Trend: Neutral
April 8, 2024 (20:45) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Cardinal Health? - Cardinal Health ( NYSE:CAH )
Cardinal Health's CAH short percent of float has fallen 19.32% since its last report. The company recently reported that it has 8.61 million shares sold short, which is 4.72% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Glaukos ( GKOS ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:29) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Boosts Patient Monitoring With smartQare Deal
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
In Article Trend: Bullish
April 8, 2024 (14:27) / "Zacks Commentary" (by Zacks Equity Research)
BD's ( BDX ) Latest Product to Offer Wider Access to Researchers
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:25) / "Zacks Commentary" (by Zacks Equity Research)
Silk Road Medical's ( SILK ) New Launch to Aid Its TCAR Portfolio
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Faces Low Testing Demand, Currency Headwinds
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
IM Cannabis ( IMCC ) Expands Business in Germany With New Alliance
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
In Article Trend: Bullish
April 8, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Should Value Investors Buy Cardinal Health ( CAH ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:35) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Penumbra ( PEN ) Stock for Now
Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:34) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Extends MRD Clinical Research With New Launch
Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
In Article Trend: Neutral
April 8, 2024 (12:18) / "Zacks Commentary" (by Zacks Equity Research)
Teleflex ( TFX ) Debuts the New Unified UroLift 2 System With ATC
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
In Article Trend: Somewhat-Bullish
April 5, 2024 (15:52) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics ( ANGO ) Q3 Earnings and Revenues Miss Estimates
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
In Article Trend: Neutral
April 5, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics' ( ANGO ) AlphaVac Gets FDA Nod for PE Treatment
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
In Article Trend: Somewhat-Bullish
April 5, 2024 (13:52) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Receives FDA's Approval for the TriClip TEER System
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
In Article Trend: Somewhat-Bullish
April 5, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Haemonetics' ( HAE ) New TEG 6s Cartridge Gets FDA Approval
Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.
In Article Trend: Somewhat-Bullish
April 5, 2024 (11:17) / "Zacks Commentary" (by Zacks Equity Research)
Henry Schein ( HSIC ) Buys TriMed to Expand in Orthopedic Space
According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.
In Article Trend: Somewhat-Bullish
April 4, 2024 (17:29) / "Benzinga" (by Zacks)
Globus Medical ( GMED ) Gains From New Launches Amid Macro Issues - DaVita ( NYSE:DVA ) , Cardinal Health ( NYSE:CAH )
Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force.
In Article Trend: Somewhat-Bullish
April 4, 2024 (17:22) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Boosts Cancer Research Suite With New Launches
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
In Article Trend: Neutral
April 4, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
Why Cardinal ( CAH ) is Poised to Beat Earnings Estimates Again
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Somewhat-Bullish
April 4, 2024 (16:03) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) New Launch to Enhance Cardiac Care
GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.
In Article Trend: Somewhat-Bullish
April 4, 2024 (16:02) / "Zacks Commentary" (by Zacks Equity Research)
Glaukos' ( GKOS ) iDose TR Receives Permanent J- Code From CMS
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
In Article Trend: Somewhat-Bullish
April 4, 2024 (15:59) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Cardinal Health ( CAH ) to Your Portfolio Now
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
In Article Trend: Somewhat-Bullish
April 4, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Ecolab ( ECL ) to Your Portfolio Now
Ecolab's (ECL) focus on research and development raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
In Article Trend: Bullish
April 4, 2024 (12:41) / "Zacks Commentary" (by Zacks Equity Research)
Globus Medical ( GMED ) Gains From New Launches Amid Macro Issues
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:24) / "Zacks Commentary" (by Zacks Equity Research)
Align ( ALGN ) Debuts Invisalign Palatal Expander in New Markets
Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.
In Article Trend: Somewhat-Bullish
April 3, 2024 (21:27) / "Zacks Commentary" (by Zacks Equity Research)
Veeva Systems ( VEEV ) Makes Change to Front Office ( revised )
Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.
In Article Trend: Somewhat-Bullish
April 3, 2024 (15:22) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Collaborates With Broad Clinical Labs
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
In Article Trend: Neutral
April 3, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain PacBio ( PACB ) Stock in Your Portfolio Now
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
In Article Trend: Somewhat-Bullish
April 3, 2024 (14:48) / "Zacks Commentary" (by Zacks Equity Research)
QuidelOrtho's ( QDEL ) QuickVue Gets FDA Nod for COVID Testing
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
In Article Trend: Neutral
April 3, 2024 (13:57) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences' ( EXAS ) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
In Article Trend: Neutral
April 3, 2024 (13:51) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy Alcon ( ALC ) Stock Right Now
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
In Article Trend: Somewhat-Bullish
April 3, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)
Veeva Systems' ( VEEV ) CFO Resignation Sparks 6% Stock Drop
Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.
In Article Trend: Somewhat-Bullish
April 3, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain CONMED ( CNMD ) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
In Article Trend: Somewhat-Bullish
April 2, 2024 (16:08) / "Zacks Commentary" (by Zacks Equity Research)
Baxter's ( BAX ) Latest FDA Approval to Boost Infusion Therapy
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:20) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Labcorp ( LH ) Stock for Now
Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:18) / "Zacks Commentary" (by Zacks Equity Research)
Three Reasons to Retain Avanos ( AVNS ) Stock in Your Portfolio
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:18) / "Zacks Commentary" (by Zacks Equity Research)
Abbott's ( ABT ) i-STAT TBI Cartridge Receives FDA Approval
Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.
In Article Trend: Neutral
April 2, 2024 (14:45) / "Benzinga" (by Globe Newswire)
Anatomic Pathology Market Size is projected to reach USD 45.27 billion by 2031, growing at a CAGR of 9.88%: Straits Research
New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- Anatomic pathology is a broad field that includes subdomains such as cytopathology, gastrointestinal pathology, gynecological pathology, musculoskeletal pathology, renal pathology, dermatopathology and immunohistochemistry, in-situ ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (14:32) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics ( ANGO ) Settles Patent Litigations With BD
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
In Article Trend: Somewhat-Bullish
April 2, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain DENTSPLY SIRONA ( XRAY ) in Your Portfolio Now
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
In Article Trend: Somewhat-Bullish
April 2, 2024 (13:06) / "Zacks Commentary" (by Zacks Equity Research)
Prestige Consumer ( PBH ) Banks on its Portfolio Amid Cost Woes
Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:36) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Debuts a New In-Line Metrology Solution
Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:31) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Invest in IDEXX ( IDXX ) Stock Right Now
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
In Article Trend: Somewhat-Bullish
April 1, 2024 (17:04) / "Zacks Commentary" (by Zacks Equity Research)
Three Reasons to Retain Revvity ( RVTY ) Stock in Your Portfolio
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 1, 2024 (17:01) / "Zacks Commentary" (by Zacks Equity Research)
OPKO Health ( OPK ) to Restructure After Asset Buyout by Labcorp
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:44) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy ResMed ( RMD ) Stock Now
Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:52) / "Zacks Commentary" (by Zacks Equity Research)
Neuronetics' ( STIM ) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Macro Issues
Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:32) / "Zacks Commentary" (by Zacks Equity Research)
Paragon 28 ( FNA ) Expands Syndesmotic Repair Line With New Launch
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add ShockWave Medical ( SWAV ) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
In Article Trend: Somewhat-Bullish
April 1, 2024 (12:15) / "Zacks Commentary" (by Zacks Equity Research)
Medtronic's ( MDT ) Newest Evolut TAVR System Gets FDA Approval
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
In Article Trend: Somewhat-Bullish
March 29, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (18:30) / "Benzinga" (by Benzinga Insights)
Here's How Much $1000 Invested In Cardinal Health 5 Years Ago Would Be Worth Today - Cardinal Health ( NYSE:CAH )
Cardinal Health CAH has outperformed the market over the past 5 years by 5.99% on an annualized basis producing an average annual return of 18.85%. Currently, Cardinal Health has a market capitalization of $27.26 billion.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
McKesson ( MCK ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Walgreens Boots ( WBA ) Q2 Earnings Top Estimates, EPS View Down
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
In Article Trend: Neutral
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) PVA to Aid in Capturing Prostate Volume
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
In Article Trend: Bullish
March 28, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
3 Reasons to Retain Inogen ( INGN ) Stock in Your Portfolio
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:17) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain STERIS ( STE ) Stock for Now
Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:04) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Lantheus ( LNTH ) to Your Portfolio
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Shockwave Medical ( SWAV ) Up on Potential Acquisition Rumors
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) and Scivita Medical Expand Partnership
Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:01) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Thermo Fisher ( TMO ) Stock
Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF ( JPME ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:29) / "Zacks Commentary" (by Zacks Equity Research)
Accuray's ( ARAY ) CyberKnife Improves Prostate Cancer Treatment
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:25) / "Zacks Commentary" (by Zacks Equity Research)
Abbott's ( ABT ) Assert-IQ Cardiac Monitor Receives CE Mark
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Zimmer Biomet ( ZBH ) Stock Now
Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
Stryker's ( SYK ) Latest Launch to Streamline Procedural Workflows
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:44) / "Zacks Commentary" (by Maharathi Basu)
5 Broker-Loved Stocks That Hold Promise Despite Volatility
We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:51) / "Zacks Commentary" (by Zacks Equity Research)
Myriad Genetics ( MYGN ) Wins Foundational Patent for MRD Assay
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:12) / "Zacks Commentary" (by Zacks Equity Research)
Masimo ( MASI ) Plans Consumer Business Spin-Off to Drive Growth
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Three Reasons to Retain Avantor ( AVTR ) Stock in Your Portfolio
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
Veeva Systems' ( VEEV ) Vault EDC Witnesses Increasing Adoption
Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:20) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Veeva Systems ( VEEV ) to Your Portfolio Now
Veeva's strong product demand and strategic deals raise optimism about the stock.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:17) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) to Sell IONIC's FDA-Cleared nCommand Lite
GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:42) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Intuitive Surgical ( ISRG ) in Your Portfolio
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:07) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Unveils QIAstat-Dx Analyzer With Remote Access
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
In Article Trend: Somewhat-Bullish
March 26, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Extends Gene Therapy Deal With NUS Medicine
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
In Article Trend: Somewhat-Bullish
March 26, 2024 (12:51) / "Zacks Commentary" (by Sweta Killa)
5 Solid Dividend Growth Stocks to Buy
NetApp (NTAP), Installed Building (IBP), Ralph Lauren (RL), Applied Materials (AMAT), and Cardinal Health (CAH) could outperform the market this year.
In Article Trend: Bullish
March 26, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
In Article Trend: Bullish
March 26, 2024 (12:44) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Align Technology ( ALGN ) Stock Now
Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Cardinal Health ( CAH ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Bullish
March 22, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Competition
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
In Article Trend: Somewhat-Bullish
March 22, 2024 (14:39) / "Zacks Commentary" (by Zacks Equity Research)
Stryker ( SYK ) Acquires SERF SAS to Aid Its Orthopedic Segment
Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Bruker Corporation ( BRKR ) Hits 52-Week High: What's Driving It?
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:41) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Inks Deal to Develop Companion Diagnostics
Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Should Value Investors Buy Cardinal Health ( CAH ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Bullish
March 22, 2024 (13:23) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold Patterson Companies ( PDCO ) in Your Portfolio
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold McKesson ( MCK ) in Your Portfolio
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
In Article Trend: Somewhat-Bullish
March 22, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
Phibro Stock ( PAHC ) Rises 7% YTD: Will the Run Continue?
Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.
In Article Trend: Bullish
March 21, 2024 (16:45) / "Zacks Commentary" (by Zacks Equity Research)
3 Reasons Growth Investors Will Love Cardinal ( CAH )
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
In Article Trend: Bullish
March 21, 2024 (16:35) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Nevro ( NVRO ) Stock for Now
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 21, 2024 (16:32) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) Renews HealthCare Alliance With Hartford
GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.
In Article Trend: Bullish
March 21, 2024 (16:04) / "Benzinga" (by Globe Newswire)
Global Pharmaceutical Supply Chain Management Market Report 2024 Highlights Strong Growth and Technological Advancements: Market Size to Reach $ 3.63 Billion in 2028
LONDON, March 21, 2024 ( GLOBE NEWSWIRE ) -- The global market for pharmaceutical supply chain management has seen significant growth in recent years, as indicated by the latest report titled " Pharmaceutical Supply Chain Management Global Market Report 2024" from The Business Research Company.
In Article Trend: Somewhat-Bullish
March 21, 2024 (15:02) / "Benzinga" (by Benzinga Insights)
Cencora Recent Insider Activity - Cencora ( NYSE:COR )
Revealing a significant insider sell on March 20, Elizabeth S Campbell, Executive Vice President at Cencora COR, as per the latest SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Campbell sold 6,977 shares of Cencora.
In Article Trend: Somewhat-Bullish
March 21, 2024 (14:05) / "Zacks Commentary" (by Zacks Equity Research)
UnitedHealth ( UNH ) Faces Investigation Following Cyberattack
A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.
In Article Trend: Neutral
March 21, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Stryker ( SYK ) Stock in Your Portfolio Now
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
In Article Trend: Bullish
March 21, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
Revvity's ( RVTY ) New Launch to Boost Research Productivity
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
In Article Trend: Somewhat-Bullish
March 21, 2024 (12:10) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain National Vision ( EYE ) Stock Now
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:23) / "Zacks Commentary" (by Zacks Equity Research)
Walgreens' ( WBA ) AllianceRx Pharmacy Will Distribute VIVJOA
Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.
In Article Trend: Somewhat-Bullish
March 20, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
HealthEquity ( HQY ) Q4 Earnings Surpass Estimates, Margins Up
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.
In Article Trend: Neutral
March 20, 2024 (15:29) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold Surmodics ( SRDX ) Stock for Now
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
In Article Trend: Somewhat-Bullish
March 20, 2024 (15:28) / "Zacks Commentary" (by Zacks Equity Research)
Merit Medical ( MMSI ) Launches FDA-Cleared Micro-Access System
Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.
In Article Trend: Somewhat-Bullish
March 20, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Accuray ( ARAY ) Stock for Now
Accuray's (ARAY) solid product demand raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 20, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Cardinal Health ( CAH ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Somewhat-Bullish
March 20, 2024 (11:55) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy Phibro ( PAHC ) Stock Now
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
In Article Trend: Somewhat-Bullish
March 20, 2024 (10:24) / "CNBC" (by Paige Tortorelli)
FDA says safety issues with China-made syringes are 'more widespread' than previously known
CNBC reviewed FDA data that shows major medical manufacturers are distributing the syringes made in China.
In Article Trend: Neutral
March 19, 2024 (18:07) / "Zacks Commentary" (by Zacks Equity Research)
Align Technology ( ALGN ) Gains From Innovation, Macro Issues Ail
In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.
In Article Trend: Neutral
March 19, 2024 (17:40) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Abbott ( ABT ) Stock Now
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
In Article Trend: Somewhat-Bullish
March 19, 2024 (17:38) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Up 21.8% YTD: What's Driving It?
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
In Article Trend: Bullish
March 19, 2024 (17:09) / "Zacks Commentary" (by Zacks Equity Research)
Inspira Technologies ( IINN ) Strives to Get AMAR Nod for ART100
The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
In Article Trend: Bullish
March 19, 2024 (14:51) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) , Nvidia Unite to Boost AI for Surgery
Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
In Article Trend: Somewhat-Bullish
March 19, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain HealthEquity ( HQY ) Stock Now
HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 19, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Cencora ( COR ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
In Article Trend: Bullish
March 19, 2024 (12:14) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Tandem Diabetes ( TNDM ) Now
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:59) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Masimo ( MASI ) to Your Portfolio Now
Masimo's (MASI) R&D activities raise optimism about the stock.
In Article Trend: Somewhat-Bullish
March 18, 2024 (16:01) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Inspire Medical ( INSP ) Stock Now
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
In Article Trend: Bullish
March 18, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Revvity's ( RVTY ) New Launch to Boost Newborn Sequencing Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
In Article Trend: Somewhat-Bullish
March 18, 2024 (15:16) / "Zacks Commentary" (by Zacks Equity Research)
Waters ( WAT ) Boosts PFAS Testing Solutions With New Cartridges
Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
High Tide ( HITI ) Acquires Queen of Bud to Expand Its Portfolio
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
In Article Trend: Bullish
March 18, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Chemed ( CHE ) Reaches a New 52-Week High: What's Driving It?
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:44) / "Zacks Commentary" (by Zacks Investment Research)
Labcorp ( LH ) Presents New Research on Precision Diagnostics
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
In Article Trend: Neutral
March 18, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain DexCom ( DXCM ) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:28) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Global Growth Robust, Macro Issues Ail
Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:27) / "Zacks Commentary" (by Zacks Equity Research)
PetIQ ( PETQ ) Broadens Minties Line With Large Dogs Dental Treats
PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:35) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Atmos Energy, Balchem, Cardinal Health, Casey's and Colgate-Palmolive
Atmos Energy, Balchem, Cardinal Health, Casey's and Colgate-Palmolive are included in this Analyst Blog.
In Article Trend: Neutral
March 18, 2024 (12:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Insulet ( PODD ) Stock Right Now
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:19) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences' ( EXAS ) BLUE-C Study Results Published in NEJM
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.
In Article Trend: Somewhat-Bullish
March 18, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the First Trust Health Care AlphaDEX ETF ( FXH ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Cardinal Health Stock In The Last 5 Years - Cardinal Health ( NYSE:CAH )
Cardinal Health CAH has outperformed the market over the past 5 years by 4.35% on an annualized basis producing an average annual return of 16.9%. Currently, Cardinal Health has a market capitalization of $26.58 billion.
In Article Trend: Somewhat-Bullish
March 15, 2024 (15:15) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) Advances AI Alliance to Improve Workflow
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
In Article Trend: Bullish
March 15, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Hits 52-Week High: What's Driving It?
Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Extends Gene Therapy Offering With New Pact
Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
In Article Trend: Neutral
March 15, 2024 (14:15) / "PR Newswire" (by Research and Markets)
$20+ Bn Advanced Wound Care Market Trends and Global Forecasts, 2035
DUBLIN, March 15, 2024 /PRNewswire/ -- The "Advanced Wound Care Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Advanced Wound Care Dressing, Type of Acute Wound Treated, Type of End User, Leading Advanced Wound Care Manufacturers, and Key Geographical Regions" ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:09) / "Zacks Commentary" (by Zacks Equity Research)
Intuitive Surgical's ( ISRG ) Da Vinci 5 Receives FDA Approval
Intuitive Surgical (ISRG) announces the FDA clearance for its next-generation robotic system, da Vinci 5, which is likely to improve surgical workflow and save significant time with better care.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:04) / "Zacks Commentary" (by Zacks Equity Research)
Waters ( WAT ) Boosts Portfolio Strength With Rheo-IS Accessory
Waters (WAT) unveils Rheo-IS accessory for its TA Instruments Discovery Hybrid Rheometers, bolstering its overall portfolio.
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Expands Strategic Alliances, Test Sales Fall
Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.
In Article Trend: Somewhat-Bullish
March 15, 2024 (12:53) / "Zacks Commentary" (by Zacks Equity Research)
Axonics ( AXNX ) Gets CE Mark for Sacral Neuromodulation System
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
In Article Trend: Bullish
March 15, 2024 (12:32) / "Zacks Commentary" (by Ritujay Ghosh)
5 Low-Beta Stocks for Safe Returns as Inflation Rises Again
Low-beta stocks like Atmos Energy Corporation (ATO), Balchem Corporation (BCPC), Cardinal Health, Inc. (CAH), Casey's General Stores, Inc. (CASY) and Colgate-Palmolive Company (CL) are a safe bet amid the ongoing market volatility.
In Article Trend: Neutral
March 15, 2024 (12:00) / "PR Newswire" (by Cardinal Health)
Cardinal Health announces approved science-based climate targets; expands focus across the supply chain
Cardinal Health announces approved science-based climate targets. expands focus across the supply chain PR ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (16:07) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold West Pharmaceutical ( WST ) in Your Portfolio Now
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
In Article Trend: Somewhat-Bullish
March 14, 2024 (15:59) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Expands Sonicare Portfolio With Latest Launch
Philips (PHG) adds Philips One for Kids toothbrush into its Sonicare family, boosting its Personal Health business.
In Article Trend: Bullish
March 14, 2024 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
BD's ( BDX ) ADC System Favored by New Study for Long-Term Care
BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
In Article Trend: Bullish
March 14, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Inari Medical's ( NARI ) ClotTriever Improves Patient Outcome
Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Envista ( NVST ) Faces Macroeconomic Challenges, FX Headwind
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:16) / "Zacks Commentary" (by Zacks Equity Research)
Inspira Technologies ( IINN ) Releases Favorable Data on VORTX
Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:46) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Charles River ( CRL ) Stock Now
Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:08) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Up 20.7% Since Last Earnings: What's Driving It?
Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Chemed's ( CHE ) VITAS Segment Inks New Deal With Covenant Care
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
In Article Trend: Bullish
March 14, 2024 (12:28) / "Zacks Commentary" (by Zacks Equity Research)
UnitedHealth's ( UNH ) Payment System Disrupted by Cyberattack
A cyberattack on UnitedHealth's (UNH) payment management subsidiary, Change Healthcare, last month continues to impact healthcare services, especially cancer treatments, as payment processing remains disrupted.
In Article Trend: Neutral
March 13, 2024 (16:01) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Globus Medical ( GMED ) Stock Now
Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
AMN Healthcare ( AMN ) Expands Capabilities of ShiftWise Flex
AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.
In Article Trend: Somewhat-Bullish
March 13, 2024 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences' ( EW ) SAPIEN TAVR Study Outcome Favorable
Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.
In Article Trend: Somewhat-Bullish
March 13, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Peering Into Cardinal Health's Recent Short Interest - Cardinal Health ( NYSE:CAH )
Cardinal Health's CAH short percent of float has risen 13.87% since its last report. The company recently reported that it has 7.78 million shares sold short, which is 4.27% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
March 13, 2024 (14:37) / "Benzinga" (by Globe Newswire)
Pharmaceutical Waste Management Market Worth USD 2.4 billion, at a 4.9% CAGR By 2031 - Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -The pharmaceutical waste management market was worth US$1.5 billion in 2022. The market is expected to expand at a CAGR of 4.9% from 2023 to 2031 and reach a total of US$ 2.4 billion by ...
In Article Trend: Neutral
March 13, 2024 (14:18) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) , AWS Unite to Scale Digital Pathology Solutions
Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.
In Article Trend: Bullish
March 13, 2024 (14:17) / "Zacks Commentary" (by Zacks Equity Research)
PacBio's ( PACB ) New Panel to Aid Its Clinical Research Solution
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:34) / "Zacks Commentary" (by Zacks Equity Research)
Alcon's ( ALC ) New Launch Strengthens IOL Innovation Leadership
Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.
In Article Trend: Somewhat-Bullish
March 13, 2024 (11:56) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Glaukos ( GKOS ) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
In Article Trend: Somewhat-Bullish
March 13, 2024 (11:56) / "Zacks Commentary" (by Zacks Equity Research)
Roche ( RHHBY ) Launches AI-Based Predictive CGM Accu-Chek
Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:04) / "Zacks Commentary" (by Zacks Equity Research)
Integra LifeSciences ( IART ) Introduces MicroMatrix Flex
Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.
In Article Trend: Neutral
March 12, 2024 (15:01) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Aids Personal Health Business With New Campaign
Philips (PHG) launches #ShareTheCare brand positioning campaign for Philips Avent, bolstering the Personal Health segment.
In Article Trend: Bullish
March 12, 2024 (15:01) / "Zacks Commentary" (by Zacks Equity Research)
Orthofix ( OFIX ) Q4 Earnings Beat Estimates, Gross Margin Up
Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:36) / "Zacks Commentary" (by Zacks Equity Research)
ClearPoint's ( CLPT ) Prism System Favored by Latest Study
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:34) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain BD ( BDX ) to Your Portfolio
BD's (BDX) slew of product launches raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:27) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Suffers due to BioPharma Softness, Stiff Competition
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
March 12, 2024 (12:22) / "Zacks Commentary" (by Zacks Equity Research)
KORU Medical ( KRMD ) Forms New Deal on Subcutaneous Infusion
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
In Article Trend: Bullish
March 12, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
In Article Trend: Somewhat-Bullish
March 12, 2024 (11:51) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Announces Advanced timsTOF Solutions at US HUPO
Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.
In Article Trend: Somewhat-Bullish
March 11, 2024 (16:33) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) AI Model to Predict Immunotherapy Response
GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.
In Article Trend: Bullish
March 11, 2024 (16:20) / "Zacks Commentary" (by Ethan Feller)
Momentum Monday: Inflation Data in Focus this Week
Want to start the week ahead of the pack? Check out Momentum Mondays ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (14:20) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Unveils CorEvitas Clinical Registry in GPP
Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:56) / "Zacks Commentary" (by Zacks Equity Research)
Cardinal Health ( CAH ) Hits 52-Week High: What's Driving It?
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:42) / "Zacks Commentary" (by Zacks Equity Research)
Fresenius Medical ( FMS ) Divests Assets to Optimize Portfolio
Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:18) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Teleflex ( TFX ) Stock for Now
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:17) / "Zacks Commentary" (by Zacks Equity Research)
Medtronic's ( MDT ) MiniMed 780G System Study Data Favorable
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
In Article Trend: Somewhat-Bullish
March 11, 2024 (12:27) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add The Cooper Companies ( COO ) to Your Portfolio Now
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
In Article Trend: Somewhat-Bullish
March 11, 2024 (12:25) / "Zacks Commentary" (by Zacks Equity Research)
Zimmer Biomet ( ZBH ) Rides on ROSA Uptake, Favorable Trend
Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Introduces Weight Loss Management Portfolio
Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:21) / "Zacks Commentary" (by Zacks Equity Research)
Integer Holdings ( ITGR ) Hits 52-Week High: What's Aiding It?
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:06) / "Zacks Commentary" (by Zacks Equity Research)
Neuronetics ( STIM ) Progresses in MRD and TRD With New Deal
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:57) / "Zacks Commentary" (by Zacks Equity Research)
DexCom's ( DXCM ) Direct-to-Watch Feature to Boost Its G7 System
DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Stereotaxis ( STXS ) Seeks Clearance for MAGiC Catheter
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:31) / "Zacks Commentary" (by Zacks Equity Research)
Alcon's ( ALC ) Vivity EDOF IOL Achieves One Million Milestone
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:23) / "Zacks Commentary" (by Maharathi Basu)
5 Stocks Favored by Brokers Amid Current Uncertainty
We believe that stocks like General Motors (GM), Cardinal Health (CAH), Deutsche Bank (DB), Group 1 (GPI) and Centene (CNC) should be on an investor's watchlist.
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:50) / "Zacks Commentary" (by Sweta Killa)
5 Dividend Stocks With High Growth Prospects
Cardinal Health (CAH), Toll Brothers (TOL), Iron Mountain (IRM), NetApp (NTAP) and Ralph Lauren (RL) have strong dividend growth prospects.
In Article Trend: Bullish
March 8, 2024 (10:44) / "Zacks Commentary" (by Zacks Equity Research)
Davita ( DVA ) Shares Gain This Week: Will the Rally Continue?
DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.
In Article Trend: Neutral
March 8, 2024 (10:41) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Soars 10% This Week: What's Fueling the Gain?
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
In Article Trend: Somewhat-Bullish
March 8, 2024 (07:06) / "Zacks Commentary" (by Zacks Equity Research)
Best Growth Stocks to Buy for March 8th
POWL, CAH and PAGS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 8, 2023.
In Article Trend: Neutral
March 7, 2024 (17:28) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Walgreens Boots ( WBA ) For Now
Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:27) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) to Reduce Childhood Malnutrition With New Pact
Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:02) / "Zacks Commentary" (by Zacks Equity Research)
Phibro ( PAHC ) Appears Well Poised on Launches, Vaccine Sales
Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
In Article Trend: Somewhat-Bullish
March 7, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)
QuidelOrtho's ( QDEL ) New Approval to Aid Pre-eclampsia Diagnosis
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.
In Article Trend: Somewhat-Bullish
March 7, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Inari Medical ( NARI ) in Your Portfolio Now
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
In Article Trend: Somewhat-Bullish
March 7, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Merit Medical ( MMSI ) Stock for Now
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
In Article Trend: Bullish
March 7, 2024 (14:40) / "Zacks Commentary" (by Zacks Equity Research)
Why Cardinal Health ( CAH ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Bullish
March 7, 2024 (12:52) / "Zacks Commentary" (by Zacks Equity Research)
Silk Road Medical's ( SILK ) New Stent Expands Its TCAR Portfolio
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
In Article Trend: Neutral
March 7, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
ResMed ( RMD ) Debuts the Smallest Full-Face CPAP Mask AirFit F40
ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:29) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold on to Neogen ( NEOG ) Stock Now
Solid progress in long-term growth strategies bodes well for Neogen (NEOG).
In Article Trend: Bullish
March 7, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Should JPMorgan Diversified Return U.S. Equity ETF ( JPUS ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (09:11) / "Benzinga" (by Globe Newswire)
Blood Collection Tubes Market Size is Projected to Reach USD 3.6 billion by 2031, Grow at a 5.4% CAGR| Analysis Report by Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The valuation of the global blood collection tube market was US $ 2.3 billion at the end of 2022. However, this valuation is forecasted to become US $ 3.6 billion by 2031.
In Article Trend: Somewhat-Bullish
March 6, 2024 (16:15) / "Zacks Commentary" (by Zacks Equity Research)
Hologic's ( HOLX ) BCI Genomic Test Study Outcome Favorable
Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.
In Article Trend: Neutral
March 6, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)
DaVita ( DVA ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about DaVita's (DVA) strength in its kidney care.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Quanterix ( QTRX ) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:49) / "Zacks Commentary" (by Zacks Equity Research)
DaVita ( DVA ) Expands Operational Footprint Via New Agreement
DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:43) / "Zacks Commentary" (by Zacks Equity Research)
Edwards ( EW ) Gains From RESILIA's Global Adoption, TAVR Growth
With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:40) / "Zacks Commentary" (by Zacks Equity Research)
Are Investors Undervaluing Cardinal Health ( CAH ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Bullish
March 6, 2024 (13:46) / "Zacks Commentary" (by Zacks Equity Research)
Stryker ( SYK ) Completes First Arthroplasty Surgery in Europe
Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
In Article Trend: Somewhat-Bullish
March 6, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
DexCom's ( DXCM ) Stelo Glucose Biosensor Receives FDA Approval
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
In Article Trend: Somewhat-Bullish
March 6, 2024 (12:11) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works
The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:59) / "Zacks Commentary" (by Vasundhara Sawalka)
4 Stocks Trading Near 52-Week High With More Upside Potential
Investors target stocks that have lately been on a bull run. Stocks like PPC, SUN, CAH and TXT are seeing price strength and have a high chance of carrying the momentum forward.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:54) / "Zacks Commentary" (by Zacks Equity Research)
Haemonetics ( HAE ) Signs Agreement to Acquire Attune Medical
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
In Article Trend: Somewhat-Bullish
March 6, 2024 (09:18) / "Zacks Commentary" (by Zacks Equity Research)
Best Growth Stocks to Buy for March 6th
PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 6, 2023.
In Article Trend: Neutral
March 5, 2024 (21:22) / "Zacks Commentary" (by Derek Lewis)
3 Top-Ranked Stocks to Buy for Stability
Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.
In Article Trend: Bullish
March 5, 2024 (17:55) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Prestige Consumer ( PBH ) Stock for Now
Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
In Article Trend: Somewhat-Bullish
March 5, 2024 (17:48) / "Zacks Commentary" (by Zacks Equity Research)
CVS Health ( CVS ) Expands In-Home Diagnostic Care With New Test
CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Ecolab ( ECL ) to Your Portfolio
Ecolab's (ECL) focus on R&D raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:15) / "Zacks Commentary" (by Zacks Equity Research)
Lantheus' ( LNTH ) DEFINITY Approved by FDA for Pediatric Use
Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.
In Article Trend: Somewhat-Bullish
March 5, 2024 (14:49) / "Zacks Commentary" (by Zacks Equity Research)
Penumbra ( PEN ) Gains From Innovation, Mounting Costs Ail
Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:28) / "Zacks Commentary" (by Zacks Equity Research)
BD ( BDX ) Initiates IDE Study to Aid Treatment of Artery Disease
BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Bruker ( BRKR ) Stock Now
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
In Article Trend: Somewhat-Bullish
March 5, 2024 (12:50) / "Zacks Commentary" (by Ritujay Ghosh)
5 Defensive Stocks to Buy as Consumer Sentiment Dips Again
Investing in defensive stocks like The Ensign Group (ENSG), Cardinal Health (CAH), Consolidated Water (CWCO), Colgate-Palmolive (CL) and American Water Works, Inc. (AWK) is a safe bet as consumer sentiment is once again sinking.
In Article Trend: Somewhat-Bullish
March 5, 2024 (12:32) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain CONMED ( CNMD ) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
In Article Trend: Somewhat-Bullish
March 4, 2024 (16:27) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Grows IC Business With New FDA Nod
The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.
In Article Trend: Somewhat-Bullish
March 4, 2024 (16:26) / "Zacks Commentary" (by Zacks Equity Research)
ICON ( ICLR ) Gains From Strategic Deals, New Innovations
ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.
In Article Trend: Bullish
March 4, 2024 (16:23) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add ShockWave Medical ( SWAV ) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:47) / "Zacks Commentary" (by Zacks Equity Research)
Cardinal Health and Humana have been highlighted as Zacks Bull and Bear of the Day
Chicago, IL - March 4, 2024 - Zacks Equity Research shares Cardinal Health ( CAH Quick QuoteCAH - ) as the Bull of the Day and Humana ( HUM Quick QuoteHUM - ) as the Bear of the Day.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Launches AI-Driven Biomedical Knowledge Base
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:27) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) , SyntheticMR Unite to Aid Brain Diagnosing Space
Philips (PHG) and SyntheticMR collaborate to launch of Smart Quant Neuro 3D, which is likely to boost the brain diagnosing field by providing automatic and precise 3D segmentation of brain tissues.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) New Launch to Enhance Precision Care
GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.
In Article Trend: Bullish
March 4, 2024 (11:23) / "Zacks Commentary" (by Zacks Equity Research)
Best Growth Stocks to Buy for March 4th
PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 4, 2023.
In Article Trend: Neutral
March 4, 2024 (10:00) / "Zacks Commentary" (by Derek Lewis)
Bull of the Day: Cardinal Health ( CAH )
Better-than-expected quarterly results have helped drive Cardinal Health's bullish move over the last year, exceeding our consensus EPS estimates by an average of 15% across its last four releases.
In Article Trend: Bullish
March 4, 2024 (09:51) / "Benzinga" (by Globe Newswire)
Blood Pressure Cuffs Market is Set to Increase to USD 1.0 billion by 2031, Registering a 6.5 % CAGR | Report by Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global blood pressure cuffs market is projected to rise at a CAGR of 6.5% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 1.0 billion is anticipated for the ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (01:12) / "PR Newswire"
Enteral Feeding Devices Market size to grow by USD 1.36 billion from 2022-2027, North America to account for 46% of ... - PR Newswire
Enteral Feeding Devices Market size to grow by USD 1.36 billion from 2022-2027, North America to account for 46% of ... PR ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (17:00) / "Zacks Commentary" (by Zacks Equity Research)
Philips' ( PHG ) CT 5300 to Boost Diagnostic Capabilities
Philips (PHG) announces its latest innovation, Philips CT 5300, which leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities.
In Article Trend: Somewhat-Bullish
March 1, 2024 (16:58) / "Zacks Commentary" (by Zacks Equity Research)
Profound Medical ( PROF ) , Siemens Unite to Treat Prostate Cancer
Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.
In Article Trend: Neutral
March 1, 2024 (16:05) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Aids Diagnostic Imaging With Philips CT 5300
Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.
In Article Trend: Bullish
March 1, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)
Best Momentum Stocks to Buy for March 1st
SPXC, CAH and TAST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 1, 2023.
In Article Trend: Neutral
March 1, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Myriad Genetics ( MYGN ) to Evaluate MRD Testing With New Pact
Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.
In Article Trend: Neutral
March 1, 2024 (14:36) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Hurt by Lower Testing Sales, Competition
Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.
In Article Trend: Somewhat-Bullish
March 1, 2024 (14:32) / "Zacks Commentary" (by Zacks Equity Research)
Veeva Systems ( VEEV ) Q4 Earnings Surpass Estimates, Margins Up
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both segments.
In Article Trend: Somewhat-Bullish
March 1, 2024 (13:43) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Omnicell ( OMCL ) Stock Now
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
In Article Trend: Somewhat-Bullish
March 1, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Inks Definitive Agreement to Acquire ELITechGroup
Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:10) / "Zacks Commentary" (by Zacks Equity Research)
Veradigm ( MDRX ) to Acquire AI Service Provider ScienceIO
Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:07) / "Zacks Commentary" (by Zacks Equity Research)
Cooper Companies ( COO ) Q1 Earnings Top, '24 Outlook Raised
Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
In Article Trend: Neutral
March 1, 2024 (11:28) / "Zacks Commentary" (by Zacks Equity Research)
New Strong Buy Stocks for March 1st
BMA, CAH, RCL, SPXC and RITM have been added to the Zacks Rank #1 (Strong Buy) List on March 1, 2023.
In Article Trend: Neutral
March 1, 2024 (11:04) / "Zacks Commentary" (by Zacks Equity Research)
Best Income Stocks to Buy for March 1st
BMA, CAH and RITM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2023.
In Article Trend: Somewhat-Bullish
February 29, 2024 (16:32) / "Zacks Commentary" (by Zacks Equity Research)
Inari Medical ( NARI ) Q4 Earnings Improve Y/Y, Gross Margin Down
Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.
In Article Trend: Neutral
February 29, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Merit Medical ( MMSI ) Q4 Earnings Top Estimates, Gross Margin Up
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.
In Article Trend: Somewhat-Bullish
February 29, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
Integra's ( IART ) Q4 Earnings Miss Estimates, Margins Down
Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.
In Article Trend: Neutral
February 29, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
Cardinal Health, Inc. ( CAH ) Hits Fresh High: Is There Still Room to Run?
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
In Article Trend: Somewhat-Bullish
February 29, 2024 (13:46) / "Zacks Commentary" (by Zacks Equity Research)
DENTSPLY SIRONA ( XRAY ) Q4 Earnings Beat Estimates, Sales Up Y/Y
DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.
In Article Trend: Somewhat-Bullish
February 29, 2024 (13:01) / "Zacks Commentary" (by Zacks Equity Research)
National Vision ( EYE ) Q4 Earnings Top Estimates, Margins Fall
National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.
In Article Trend: Somewhat-Bullish
February 29, 2024 (12:29) / "Zacks Commentary" (by Zacks Equity Research)
Nevro ( NVRO ) Gets FDA Nod for SI Fixation Without Lateral Screw
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
In Article Trend: Somewhat-Bullish
February 29, 2024 (11:37) / "Zacks Commentary" (by Zacks Equity Research)
Chemed ( CHE ) Q4 Earnings Surpass Estimates, Margins Expand
Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.
In Article Trend: Somewhat-Bullish
February 28, 2024 (18:30) / "Benzinga" (by Benzinga Insights)
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today - Cardinal Health ( NYSE:CAH )
Cardinal Health CAH has outperformed the market over the past 5 years by 4.65% on an annualized basis producing an average annual return of 17.29%. Currently, Cardinal Health has a market capitalization of $26.63 billion.
In Article Trend: Somewhat-Bullish
February 28, 2024 (17:45) / "Zacks Commentary" (by Zacks Equity Research)
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal ( CAH )
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
In Article Trend: Bullish
February 28, 2024 (15:20) / "Benzinga" (by PRNewswire)
Crown Castle Co-Founder Ted B. Miller Files Lawsuit to Invalidate Crown Castle's Unlawful Cooperation Agreement with Elliott - Crown Castle ( NYSE:CCI )
Asserts That Crown Castle's Cooperation Agreement Struck Prior to Company's Nomination Window Disenfranchises Shareholders and Entrenches Board Cooperation Agreement Granted Two Board Seats and Does Not Require Elliott to Retain Equity Ownership in Company, Thereby Misaligning Elliott's ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (14:47) / "Zacks Commentary" (by Zacks Equity Research)
Philips' ( PHG ) New Innovation to Boost Neurovascular Diagnosis
Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.
In Article Trend: Bullish
February 28, 2024 (14:30) / "Zacks Commentary" (by Zacks Equity Research)
Patterson Companies ( PDCO ) Misses on Q3 Earnings, Lowers EPS View
Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.
In Article Trend: Neutral
February 28, 2024 (14:22) / "Zacks Commentary" (by Zacks Equity Research)
Inogen ( INGN ) Q4 Earnings Miss Estimates, Gross Margin Improves
Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
In Article Trend: Neutral
February 28, 2024 (14:04) / "Zacks Commentary" (by Zacks Equity Research)
Masimo ( MASI ) Q4 Earnings Beat Estimates, Margins Decline
Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.
In Article Trend: Neutral
February 28, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
OPKO Health's ( OPK ) Q4 Earnings Match Estimates, Revenues Top
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
In Article Trend: Neutral
February 28, 2024 (13:59) / "Zacks Commentary" (by Zacks Equity Research)
Insulet ( PODD ) Q4 Earnings, Revenues Top Mark, Margins Expand
In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.
In Article Trend: Neutral
February 28, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Myriad Genetics ( MYGN ) Q4 Earnings Top Estimate, Margins Down
Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.
In Article Trend: Neutral
February 28, 2024 (10:53) / "Zacks Commentary" (by Zacks Equity Research)
Alcon ( ALC ) Q4 Earnings Beat Estimates, Margins Expand
Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.
In Article Trend: Somewhat-Bullish
February 27, 2024 (19:30) / "Zacks Commentary" (by Benjamin Rains)
How to Find Top-Ranked Stocks to Buy in March
Exploring how investors can use the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy in March and throughout what looks set to be a strong 2024.
In Article Trend: Somewhat-Bullish
February 27, 2024 (17:21) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain STERIS ( STE ) Stock for Now
Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
In Article Trend: Somewhat-Bullish
February 27, 2024 (17:19) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics' ( DGX ) New Pact to Reduce Food Insecurity
Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
In Article Trend: Somewhat-Bullish
February 27, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) , Biofourmis Partner to Boost At-Home Care
GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.
In Article Trend: Bullish
February 27, 2024 (16:09) / "Zacks Commentary" (by Zacks Equity Research)
McKesson ( MCK ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
In Article Trend: Somewhat-Bullish
February 27, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
Alcon ( ALC ) Faces Rising Expenses, Tough Competitive Scenario
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
In Article Trend: Somewhat-Bullish
February 27, 2024 (15:28) / "Fox Business News" (by Daniella Genovese)
Eye products sold at Walmart, CVS could pose infection risk
Eye ointment products sold at CVS and Walmart stores nationwide are being recalled due to a potential risk of infection, federal health officials said. Brassica Pharma Pvt.
In Article Trend: Somewhat-Bearish
February 27, 2024 (15:03) / "Zacks Commentary" (by Zacks Equity Research)
Quanterix ( QTRX ) Expands in Alzheimer's Testing With Alliances
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
In Article Trend: Somewhat-Bullish
February 27, 2024 (13:44) / "Zacks Commentary" (by Zacks Equity Research)
Henry Schein ( HSIC ) Q4 Earnings Miss, Operating Margin Down
Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.
In Article Trend: Neutral
February 27, 2024 (08:01) / "Zacks Commentary" (by Zacks Equity Research)
Best Growth Stocks to Buy for February 27th
POWL, CAH and TXT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2023.
In Article Trend: Somewhat-Bullish
February 27, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Composite Rating For Cardinal Health Jumps To 96
The IBD SmartSelect Composite Rating for Cardinal Health ( CAH ) rose from 92 to 96 Tuesday. X The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. Cardinal Health is trading within the buy zone from a 108.39 entry ...
In Article Trend: Somewhat-Bullish
February 26, 2024 (19:14) / "Zacks Commentary" (by Ethan Feller)
Momentum Monday: Bull Market Continues
Want to start the week ahead of the pack? Check out Momentum Mondays ...
In Article Trend: Neutral
February 26, 2024 (16:54) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Edward Lifesciences ( EW ) Stock Now
Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.
In Article Trend: Somewhat-Bullish
February 26, 2024 (16:42) / "Zacks Commentary" (by Zacks Equity Research)
Penumbra ( PEN ) Q4 Earnings Top Estimates, Margins Increase
Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.
In Article Trend: Neutral
February 26, 2024 (16:01) / "Zacks Commentary" (by Zacks Equity Research)
ClearPoint Neuro ( CLPT ) Gets FDA's Nod for New Software
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
In Article Trend: Somewhat-Bullish
February 26, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Lantheus ( LNTH ) to Your Portfolio
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
In Article Trend: Somewhat-Bullish
February 26, 2024 (15:52) / "Zacks Commentary" (by Zacks Equity Research)
Bruker's ( BRKR ) New Launches Drive Growth Amid FX Woes
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
In Article Trend: Somewhat-Bullish
February 26, 2024 (15:33) / "Benzinga" (by Globe Newswire)
Pediatric Medical Devices Market Set to Hit USD 47.4 billion by 2031, with 6.3% CAGR: Analysis by Transparency Market Research, Inc.
Wilmington, Delaware, United States, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global pediatric medical devices market was projected to attain US$ 27.6 billion in 2022. It is anticipated to garner a 6.3% CAGR from 2023 to 2031 and by 2031, the market is likely to ...
In Article Trend: Somewhat-Bullish
February 26, 2024 (14:22) / "Zacks Commentary" (by Zacks Equity Research)
Philips' ( PHG ) New Innovation to Boost Radiation-Free Imaging
Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.
In Article Trend: Somewhat-Bullish
February 26, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Hold Labcorp ( LH ) Stock for Now
Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).
In Article Trend: Somewhat-Bullish
February 26, 2024 (13:41) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Forges Collaboration With Wheeler Bio
Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.
In Article Trend: Somewhat-Bullish
February 24, 2024 (18:31) / "MarketWatch" (by Silvia Ascarelli)
We want to retire to somewhere our kids and grandkids would want to live too. Our budget is $7,000 a month - where should we go?
Looking for ideas on the best place for you to retire? Email ...
In Article Trend: Somewhat-Bullish
February 23, 2024 (16:31) / "Zacks Commentary" (by Zacks Investment Research)
Amedisys' ( AMED ) Q4 Earnings Miss Estimates, Margins Up
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.
In Article Trend: Neutral
February 23, 2024 (16:14) / "Zacks Commentary" (by Zacks Equity Research)
BD ( BDX ) , Camtech Health Unite to Aid Cervical Cancer Screening
BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.
In Article Trend: Neutral
February 23, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
Lantheus ( LNTH ) Q4 Earnings Surpass Estimates, Gross Margin Up
Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.
In Article Trend: Neutral
February 23, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
3 Reasons to Hold Inogen ( INGN ) Stock in Your Portfolio for Now
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
In Article Trend: Somewhat-Bullish
February 23, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Teleflex ( TFX ) Q4 Earnings Top Estimates, Operating Margin Falls
Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.
In Article Trend: Neutral
February 23, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
Best Growth Stocks to Buy for February 23rd
CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.
In Article Trend: Neutral
February 23, 2024 (13:07) / "Zacks Commentary" (by Zacks Equity Research)
Best Value Stocks to Buy for February 23rd
BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.
In Article Trend: Somewhat-Bullish
February 23, 2024 (12:43) / "Zacks Commentary" (by Zacks Equity Research)
Veracyte's ( VCYT ) Q4 Loss Widens, Gross Margin Expands
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
In Article Trend: Neutral
February 23, 2024 (12:35) / "Zacks Commentary" (by Zacks Equity Research)
Best Income Stocks to Buy for February 23rd
AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.
In Article Trend: Somewhat-Bullish
February 23, 2024 (12:04) / "Zacks Commentary" (by Zacks Equity Research)
New Strong Buy Stocks for February 23rd
IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.
In Article Trend: Neutral
February 23, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Owens & Minor Clears Key Benchmark, Hitting 80-Plus RS Rating
The Relative Strength ( RS ) Rating for Owens & Minor ( OMI ) climbed into a new percentile Friday, with a rise from 79 to 84. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Bullish
February 22, 2024 (21:35) / "Zacks Commentary" (by Zacks Equity Research)
ICON ( ICLR ) Q4 Earnings Surpass Estimates, Margins Expand
ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.
In Article Trend: Neutral
February 22, 2024 (15:55) / "Zacks Commentary" (by Zacks Equity Research)
Better Therapeutics' ( BTTX ) CBT Gains FDA's Breakthrough Status
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
In Article Trend: Somewhat-Bullish
February 22, 2024 (15:50) / "Zacks Commentary" (by Zacks Equity Research)
Nevro's ( NVRO ) Q4 Earnings and Sales Top Estimates, Margins Up
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
In Article Trend: Neutral
February 22, 2024 (15:22) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences ( EXAS ) Q4 Loss Narrows, Revenues Rise Y/Y
Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.
In Article Trend: Neutral
February 22, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Cardinal Health ( CAH ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
February 22, 2024 (13:58) / "Zacks Commentary" (by Zacks Equity Research)
Glaukos ( GKOS ) Q4 Earnings Miss Estimates, Revenues Rise Y/Y
Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.
In Article Trend: Neutral
February 22, 2024 (13:31) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Posts Wider Q4 Loss, Gross Margin Down
Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.
In Article Trend: Neutral
February 22, 2024 (12:41) / "Zacks Commentary" (by Maharathi Basu)
5 Stocks Favored by Brokers Amid the Current Uncertainty
We believe that stocks like Deutsche Bank (DB), Cross Country Healthcare (CCRN), Bread Financial (BFH), American Axle (AXL) and Cardinal Health (CAH) should be on an investor's watchlist.
In Article Trend: Somewhat-Bullish
February 22, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Showing Rising Market Leadership: Cardinal Health Earns 81 RS Rating
On Thursday, Cardinal Health ( CAH ) got an upgrade to its Relative Strength ( RS ) Rating, from 78 to 81. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
In Article Trend: Somewhat-Bullish
February 21, 2024 (16:58) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Align Technology ( ALGN ) Stock Now
Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.
In Article Trend: Somewhat-Bullish
February 21, 2024 (16:54) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Surges 4.6%: Will the Rally Continue?
Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.
In Article Trend: Somewhat-Bullish
February 21, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Gains From CRADL Amid Soft Market Scenario
Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
In Article Trend: Somewhat-Bullish
February 21, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Global Nitrile Gloves Market Size is Estimated to Reach USD 13.53 billion by 2030, Growing at a CAGR of 5.30%: Straits Research
New York, United States, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- The high puncture resistance and dexterous strength of nitrile gloves make them a popular choice in the medical sector. In addition to being less frictional and having a longer shelf life than latex gloves, nitrile gloves are more ...
In Article Trend: Somewhat-Bullish
February 21, 2024 (15:25) / "Zacks Commentary" (by Zacks Equity Research)
Sight Sciences ( SGHT ) to Expand in Europe With New Launch
By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.
In Article Trend: Bullish
February 21, 2024 (14:37) / "Zacks Commentary" (by Zacks Equity Research)
Avanos ( AVNS ) Q4 Earnings Lag Estimates, Margins Contract
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.
In Article Trend: Neutral
February 21, 2024 (12:17) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Zimmer Biomet ( ZBH ) Stock Now
Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).
In Article Trend: Somewhat-Bullish
February 21, 2024 (12:13) / "Zacks Commentary" (by Zacks Equity Research)
Globus Medical ( GMED ) Q4 Earnings Surpass, Margins Down
Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.
In Article Trend: Somewhat-Bullish
February 21, 2024 (12:00) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
GAITHERSBURG, Md., Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) , a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C.
In Article Trend: Somewhat-Bullish
February 21, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO - Emergent BioSolutions ( NYSE:EBS ) , Bausch & Lomb ( NYSE:BLCO )
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc.
In Article Trend: Somewhat-Bullish
February 20, 2024 (19:19) / "Zacks Commentary" (by Zacks Equity Research)
Medtronic ( MDT ) Q3 Earnings Beat Estimates, 2024 View Up
Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.
In Article Trend: Somewhat-Bullish
February 20, 2024 (18:35) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain ResMed ( RMD ) Stock for Now
Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.
In Article Trend: Somewhat-Bullish
February 20, 2024 (16:28) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) Tie-Up to Improve Care Accessibility
GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.
In Article Trend: Bullish
February 20, 2024 (16:27) / "Zacks Commentary" (by Zacks Equity Research)
Three Reasons to Retain Accuray ( ARAY ) Stock in Your Portfolio
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
In Article Trend: Somewhat-Bullish
February 20, 2024 (15:25) / "Zacks Commentary" (by Zacks Equity Research)
Illumina ( ILMN ) Rides on NGS Portfolio Expansion Amid Macro Woe
In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.
In Article Trend: Somewhat-Bullish
February 20, 2024 (15:17) / "Zacks Commentary" (by Zacks Equity Research)
SenesTech ( SNES ) Expands in the Netherlands With Q-chem Deal
SenesTech's (SNES) collaboration with Q-chem strategically aligns with the Netherlands' Integrated Pest Control program.
In Article Trend: Somewhat-Bullish
February 20, 2024 (14:40) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website